Tonix製藥控股 TNXP 深 滬
等待開盤 11-04 09:30:00 美东时间
5.19
+0.040
+0.78%
華盛通- 最 高5.39
- 今 開5.16
- 成交量 48.82万股
- 最 低 5.16
- 昨 收 5.15
- 總市值 8901.38万
- 52周最高 20.56
- 市盈率 靜 --
- 換手率 2.85%
- 52周最低 4.96
- 委 比 -63.51%
- 總股本 1715.10万
- 歷史最高 13440000000.00
- 量 比 0.73
- 振 幅 4.47%
- 歷史最低 4.96
- 每 手 1
- 風險率 3.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tonix Pharmaceuticals Holding Co收涨0.98%，成交额319.12万美元
11月3日，Tonix Pharmaceuticals Holding Co（TNXP）收涨0.98%，报5.15美元，成交额319.12万美元，市值8832...
11-03 08:04
美股大行评级 | 潜在涨幅101.01%！Stifel上调ORIC Pharmaceuticals目标价至18美元，维持"买入"评级
今日重点评级关注：Stifel：维持ORIC Pharmaceuticals"买入"评级，目标价从14美元升至18美元；花旗：维持Liberty Energy"买入"评级，目标价从27.5美元升至28美元
10-27 12:30
Canaccord Genuity Initiates Coverage On Tonix Pharmaceuticals with Buy Rating, Announces Price Target of $18
Canaccord Genuity analyst Gary Nachman initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with a Buy rating and announces Price Target of $18.
10-26 20:18
Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026
Tonix Pharmaceuticals Holding Corp. will host a conference call and webcast on November 9, 2026, at 8:30 a.m. ET to discuss third quarter 2026 financial results and operational highlights. Registration links for the call and webcast are provided. Tonix, a biopharmaceutical company, focuses on CNS disorders, infectious diseases, and immunology. Its flagship product, TONMYA®, is the first treatment for fibromyalgia in over 15 years. The company is ...
10-26 11:00
Tonix Pharmaceuticals Holding Co收涨0.78%，成交额385.26万美元
10月24日，Tonix Pharmaceuticals Holding Co（TNXP）收涨0.78%，报5.17美元，成交额385.26万美元，市值886...
10-24 07:09
Tonix Pharmaceuticals Holding Co收跌5.92%，成交额576.89万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:06
Tonix Pharma Files Technical Regulatory Disclosure Update
The latest announcement is out from Tonix Pharma ( ($TNXP) ). In a brief filing...
10-15 19:29
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026
Tonix Pharmaceuticals will present TNX-801, a live, attenuated horsepox virus-based vaccine platform for mpox and other infectious diseases, at the World Vaccine Congress Europe in Amsterdam on October 21, 2026. The presentation, titled "TNX-801 Vaccine Platform Safety and Efficacy," will be led by Farooq Nasar, Ph.D., MPH. Additionally, Tonix will host a working group session on "Vectored Vaccine Platforms: From Design to Improving Efficacy" on ...
10-15 11:00
Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic TONMYA On Oct 1; Paragraph IV Certification Challenges Four TONMYA Patents Listed In FDA Orange Book; Co Intends To Enforce TONMYA Intellectual Property Rights
On October 1, 2026, Tonix Pharmaceuticals Holding Corp. (the "Company") received a notice (the "Notice") from Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively, "DRL") stating that DRL filed an Abbreviated New Drug Application ("ANDA") containing a Paragraph IV patent ce...
10-03 05:32
Tonix Pharmaceuticals Announces Second Major Managed Medicare Agreement For TONMYA
Agreement for the treatment of fibromyalgia in adults that is effective immediately, adding approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.). Medicare coverage now totals 32 million Medicare lives in the U.S. (58% of approximately 55 million Medica...
09-22 19:09
